SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance with dematerialization actions for the quarter ended 30 September 2026.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced the voting results of its 38th Annual General Meeting (AGM), where all resolutions were passed with requisite majority. The company also declared a dividend on its equity shares for the financial year 2025-26.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd held its 38th Annual General Meeting (AGM) on September 29, 2026, through video conference. The meeting was attended by the Chairman, Managing Director, and several directors. The company provided an e-voting facility to shareholders to cast their votes. The AGM transacted several items of business, including the adoption of audited standalone and consolidated financial statements.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has closed its trading window for all designated persons and their immediate relatives from 01st October, 2026 till 48 hours after the declaration of financial results for the Second quarter and half year ended 30th September, 2026.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has dispatched a letter to shareholders providing a web-link and QR code to access the Integrated Annual Report for FY 2025-26. The company has also announced the 38th Annual General Meeting (AGM) to be held on September 29, 2026, and proposed a dividend of Rs. 0.40 per equity share.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as required by SEBI regulations.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced the notice of its 38th Annual General Meeting (AGM) to be held on September 29, 2026, through video conferencing. The company has also released its annual report for the financial year 2025-26, which includes details of the company's performance, governance, and future plans.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced its Annual Report for the Financial Year 2025-26, along with the notice of its 38th Annual General Meeting (AGM) scheduled for September 29, 2026. The company has also provided details for the AGM, including record date for dividend, cut-off date for e-voting eligibility, and book closure dates.

SMS Pharmaceuticals Ltd

CARE Ratings Limited has reaffirmed the credit ratings of SMS Pharmaceuticals Ltd, assigning a 'CARE A' rating with a stable outlook for the company's long-term bank facilities and a 'CARE A1' rating for its short-term bank facilities.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has published a newspaper advertisement informing shareholders about the 38th Annual General Meeting to be held on September 29, 2026, through Video Conference or Other Audio Visual Means.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has changed the record date for dividend from 16th September, 2026 to 22nd September, 2026.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has changed the date of its 38th Annual General Meeting from 23rd September, 2026 to 29th September, 2026, due to unavoidable circumstances and administrative constraints.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced the publication of a newspaper advertisement regarding its 38th Annual General Meeting to be held through Video Conference/Other Audio Visual Means on September 23, 2026.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced an intimation on tax deduction at source on dividend. The company has recommended a final dividend of Rs.0.40 per equity share for the financial year ended March 31, 2026, subject to approval by shareholders at the ensuing Annual General Meeting. The record date for determining entitlement to the final dividend is fixed as Wednesday, 16th September, 2026.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced its audited standalone and consolidated financial results for the first quarter ended June 30, 2026, which are available on its website and in newspapers.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has released its Q1FY27 investor presentation, highlighting a 6% YoY revenue growth, sustained EBITDA margin of ~20%, and an 8% YoY PAT growth. The company has completed 4 DMF/CEP filings and is on track to meet its FY27 target of 10 filings. A ₹280 crore capex programme is progressing as planned, and the board has approved an infusion of up to ₹50 crore into its subsidiary SMS Peptides Private Limited.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd reported a 6% YoY growth in revenue for Q1FY27, driven by broad-based growth across high-value APIs, with gross margin remaining above 45% and EBITDA margin sustained at ~20%. The company completed 4 DMF/CEP filings and is on track to meet its FY27 target of 10 filings. A ₹280 crore capex programme is progressing as planned, and the company has approved an infusion of up to ₹50 crore into its subsidiary SMS Pepdes Private Limited.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd announced its Q1 FY2026 financial results, with a profit before tax of Rs. 2,814.42 lakhs. The company also approved the re-appointment of Mr. Ramesh Babu Potluri as Managing Director for a term of 5 years. Additionally, the board approved giving a loan to its subsidiary, SMS Peptides Private Limited, up to Rs. 50 crores.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd has announced the fixation of record date for its 38th Annual General Meeting (AGM) and the payment of dividend for the financial year 2025-26. The company has also approved the standalone and consolidated un-audited financial results for the first quarter ended 30th June, 2026. Additionally, the Board of Directors has re-appointed Mr. Ramesh Babu Potluri as the Chairman and Managing Director of the company for a term of 5 years.

SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd re-appoints Ramesh Babu Potluri as Managing Director for 5 years. The company also approved the standalone and consolidated un-audited Financial Results for the first quarter ended 30th June, 2026. Additionally, the Board approved the loan to be given to SMS Peptides Private Limited, a subsidiary company, up to an aggregate amount not exceeding Rs. 50 Crores.